Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
B cells mediate chronic allograft rejection independently of antibody production
Qiang Zeng, Yue-Harn Ng, Tripti Singh, Ke Jiang, Khaleefathullah A. Sheriff, Renee Ippolito, Salwa Zahalka, Qi Li, Parmjeet Randhawa, Rosemary A. Hoffman, Balathiripurasundari Ramaswami, Frances E. Lund, Geetha Chalasani
Qiang Zeng, Yue-Harn Ng, Tripti Singh, Ke Jiang, Khaleefathullah A. Sheriff, Renee Ippolito, Salwa Zahalka, Qi Li, Parmjeet Randhawa, Rosemary A. Hoffman, Balathiripurasundari Ramaswami, Frances E. Lund, Geetha Chalasani
View: Text | PDF
Brief Report Immunology

B cells mediate chronic allograft rejection independently of antibody production

  • Text
  • PDF
Abstract

Chronic rejection is the primary cause of long-term failure of transplanted organs and is often viewed as an antibody-dependent process. Chronic rejection, however, is also observed in mice and humans with no detectable circulating alloantibodies, suggesting that antibody-independent pathways may also contribute to pathogenesis of transplant rejection. Here, we have provided direct evidence that chronic rejection of vascularized heart allografts occurs in the complete absence of antibodies, but requires the presence of B cells. Mice that were deficient for antibodies but not B cells experienced the same chronic allograft vasculopathy (CAV), which is a pathognomonic feature of chronic rejection, as WT mice; however, mice that were deficient for both B cells and antibodies were protected from CAV. B cells contributed to CAV by supporting splenic lymphoid architecture, T cell cytokine production, and infiltration of T cells into graft vessels. In chimeric mice, in which B cells were present but could not present antigen, both T cell responses and CAV were markedly reduced. These findings establish that chronic rejection can occur in the complete absence of antibodies and that B cells contribute to this process by supporting T cell responses through antigen presentation and maintenance of lymphoid architecture.

Authors

Qiang Zeng, Yue-Harn Ng, Tripti Singh, Ke Jiang, Khaleefathullah A. Sheriff, Renee Ippolito, Salwa Zahalka, Qi Li, Parmjeet Randhawa, Rosemary A. Hoffman, Balathiripurasundari Ramaswami, Frances E. Lund, Geetha Chalasani

×

Figure 1

B cells are sufficient for CAV in the absence of antibodies.

Options: View larger image (or click on image) Download as PowerPoint
B cells are sufficient for CAV in the absence of antibodies.
WT, AID/μS ...
WT, AID/μS KO, μMT, and μMT + B cellsAID/μSKO recipients were transplanted with BALB/c hearts and treated with costimulation blockade (0.25 mg, CTLA4Ig and anti-CD40L, on days 2, 4, 6, and 8). μMT + B cellsAID/μSKO recipients were μMT mice that received naive AID/μS KO B cells (2 × 107, 2 to 4 days before transplantation). Allografts were beating and contracting at harvest (100–110 days). (A and B) Morphometric quantitation of vasculopathy in each recipient (A), and luminal occlusion in each vessel (B) (mean ± SEM; n = 26–64 vessels, 5–9 mice per group). (C) Morphometric quantitation of luminal occlusion in each vessel in Bm12 heart allografts from untreated recipients (at 90–100 days, mean ± SEM; n = 34–87 vessels, 5–10 mice per group). (D) Median fluorescence intensity of BALB/c-reactive antibodies in sera of BALB/c heart recipients at harvest (1:4 dilution, mean ± SD; n = 4–6 mice per group). *P < 0.05; **P < 0.005; ***P < 0.0005.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts